Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Investor Presentation (January 2021)
11 slides from Bioporto A/s's investor presentation, Jan 4, 2021
Slide 1: Investor update @ HC Andersen Capital
Investor update @ HC Andersen Capital January 4, 2021 © Copyright BioPorto CONFIDENTIAL
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company”) and any further information that may be made available in connection with the subject matter contained her
Slide 3: BioPorto's gRAD: A Development Platform
BioPorto’s gRAD A Development Platform © Copyright BioPorto CONFIDENTIAL 3
Slide 4: Highlights gRAD
BioPorto’s patented lateral flow development system Highlights gRAD • Rapid development of lateral flow tests See how gRAD works • High accuracy – same level as the ELISA test • Multi sample types – plasma, urine, saliva etc. • Semi-quantitative test result • Fast test – from sample to result ~10 mi
Slide 5: gRAD: Platform for Product Development & Growth
gRAD Platform for Product Development & Growth NGAL COVID Leveraging the gRAD platform, BioPorto is developing tests for NGAL as well as three emerging applications: Viral 1. NGAL: for near-patient assessment of kidney injury gRAD 2. COVID-19: a viral diagnostic test Platform 3. COVID-19: a serology
Slide 6: Generic Rapid Assay Device (gRAD) platform
Generic Rapid Assay Device (gRAD) platform Positive Negative BioPorto’s patented Generic Rapid Assay Device (gRAD) technology is a lateral flow test development platform with no analyte-specific reagents on the strip. Instead, labelled capture antibodies and gold nanoparticle conjugated detection an
Slide 7: NGALds for Near-Patient Testing
NGALds for Near-Patient Testing • NGALds is the first assay developed and approved on the gRAD platform • CE Mark in Europe on December 30, 2020 • A rapid lateral flow test to offer semi-quantitative urine NGAL results without complexity or instrumentation – ideal for outpatient or low-resource sett
Slide 8: NGALds potential
NGALds potential • High accuracy and high correlation to our lab test The NGAL Test • Broaden testing for Acute Kidney Injury • The NGAL Test: Lab test at Hospitals • NGALds: Point of care test at Hospitals (bedside test) and at General Practitioner • In the future NGALds can also be used as a home
Slide 9: COVID-19 viral test development process
COVID-19 viral test development process Assay Development Timeline Analytical Clinical trial Start patient Clinical testing agreements enrollment testing Clinical Regulatory results submissions © Copyright BioPorto CONFIDENTIAL 9
Slide 10: COVID-19 viral test completed and advanced for clinical testing
COVID-19 viral test completed and advanced for clinical testing • Completion of successful antibody pairing, device prototyping and production agreements • BioPorto has provided test kits to the University of California, Davis (US) to test samples from approx. 150 COVID-19 patients • Results are exp
Slide 11: Financial Calendar 2021
Financial Calendar 2021 March 17, 2021 Annual report 2020 April 29, 2021 Annual General Meeting May 12, 2021 Q1 2021 Results August 18, 2021 Q2 2021 Results November 17, 2021 Q3 2021 Results Contact: Ole Larsen (CFO) ol@bioporto.com © Copyright BioPorto CONFIDENTIAL